Last updated on January 2019

Safety and Pharmacokinetics of REGN2810 (Anti-PD-1) in Japanese Patients With Advanced Malignancies


Brief description of study

The primary objective of the study is to assess the safety, tolerability, and Pharmacokinetics (PK) of REGN2810 in Japanese patients with advanced malignancies. The secondary objective of the study is to assess the immunogenicity of REGN2810.

Clinical Study Identifier: NCT03233139

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.